Articles tagged with Cancer Patients
A new study reveals that disparities in cancer stage and treatment account for the majority of excess deaths among uninsured and Medicaid-insured rectal cancer patients. Improving insurance coverage and reducing cost-related barriers to primary care and high-quality treatment can help mitigate these disparities.
A recent analysis found that 18% of US cancer survivors, equating to over two million individuals, did not receive necessary medical services in the previous year due to financial worries. Cancer survivors under 65 were 55% more likely to delay or forgo all types of medical care than their non-cancer peers.
Researchers at TGen and VARI discovered a biomarker, miR-92a-2*, linked to survival in SCLC patients. Higher tumor levels of this microRNA are associated with chemoresistance and decreased survival.
A meta-analysis of publicly available data from randomised trials found that patients taking ARBs had a significantly increased likelihood of new cancer diagnosis compared with patients in control groups. The study also found a modestly increased risk of lung cancer among ARB users, but no significant excess in cancer deaths.
UAB researchers are investigating the role of inactivated DNA left behind after breast-cancer treatment. They aim to understand how this altered DNA activates cancer's deadly spread, a process called metastasis. The study could lead to improved prevention and treatment for millions of cancer patients.
A decade-long Phase III clinical trial found that selenium has no benefit in reducing the risk of developing lung cancer, either a recurrence or second primary malignancy. The study involved 1,522 Stage I non-small cell lung cancer patients and showed that selenium had minimal side effects but failed to demonstrate any protective effect.
Researchers found that cancer cells lacking COMMD1 are more invasive and likely to metastasize, suggesting a possible drug target. Enhanced COMMD1 levels in mouse melanoma cells reduced metastatic lung tumors.
Vandetanib significantly prolongs progression-free survival and improves response rates compared to standard chemotherapy alone in previously treated advanced NSCLC patients. The addition of vandetanib also reduces symptoms and increases time to worsening of symptoms.
Researchers from John Theurer Cancer Center present studies on first-line treatments for aggressive lymphoma, the efficacy of genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma. Findings include a high complete remission rate with rituximab-FND combination therapy and better survival rates...
The John Theurer Cancer Center is presenting 16 research abstracts on various areas of oncology during the ASCO Annual Meeting. These studies include Phase I and II trials for multiple myeloma, lymphoma, and cutaneous T-cell lymphoma treatments.
Ihor S. Sawczuk, M.D., Co-Chief of the Division of Urologic Oncology, presents research on laparoscopic adrenalectomy and robot-assisted radical prostatectomy for recurrent prostate cancer. The John Theurer Cancer Center showcases its expertise in urologic oncology through these innovative treatments.
Researchers at Henry Ford Hospital found that adenocarcinoma of the bladder has a poor overall survival rate, but certain factors can improve prognosis. Patients diagnosed at age 60 or younger and those with well-differentiated, localized tumors may have better chances of survival.
Researchers tested methylphenidate, a psychostimulant medication, to treat cancer-related fatigue. While the study found no significant difference between treatment and placebo groups, there was a trend of improved satisfaction with treatment among patients receiving methylphenidate, particularly those with stage III/IV cancer.
Cancer patients can benefit from moderate-intensity aerobic exercise, tailored to individual needs, to improve quality of life, muscular strength, and reduce the risk of recurrence for breast cancer patients. Exercise also helps maintain lean body mass, contributing to increased well-being.
Researchers found that Wikipedia's cancer information is accurate but poorly readable compared to peer-reviewed sites like the National Cancer Institute's PDQ. Readability was highly statistically significant, with Wikipedia written at a college level while PDQ was suitable for a 9th grader.
Men who choose radiotherapy over surgery for prostate cancer have a 17% improvement in overall survival rate, with patients refusing treatment having a 51% 10-year survival rate. This study highlights the importance of considering treatment options when diagnosed with prostate cancer.
A new Mayo Clinic study found that complete removal of all tumors that spread can significantly improve prognosis for kidney cancer patients. Patients who underwent complete tumor removal had an average cancer-specific survival rate of 5 years, compared to just 1 year for those without metastatic tumors removed.
Research from Fox Chase Cancer Center shows that patients with stage IIIA non-small cell lung cancer (NSCLC) who receive surgery, particularly lobectomy, have increased overall survival rates. This is in contrast to those who received chemoradiation alone.
A large Phase III randomized trial of shark cartilage as a cancer agent found no survival benefit for patients with advanced non-small cell lung cancer. The study enrolled 379 newly-diagnosed patients and did not meet its primary endpoint: survival.
A study of 125,126 Swedish citizens with type 2 diabetes found an increased risk of 24 types of cancer, with the highest rates for pancreatic and liver cell cancers. The researchers also discovered a lower risk of prostate cancer among diabetics with a family history of the disease.
A new surgical procedure called hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to increase the survival of children with desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. Patients who received HIPEC had a 3-year survival rate of 71%, compared to 26% for those who received only standard treatment.
Researchers found eGFR to be equally valuable as Ccr for assessing preoperative renal function in gastric cancer patients, with significant correlations between postoperative sCr and both eGFR and Ccr. The study suggests eGFR may replace Ccr in clinical practice due to its clear advantages.
Researchers at Henry Ford Hospital found that exercise programs like ExCITE improve quality of life and reduce fatigue in breast and prostate cancer patients. The study, which followed patients for one year after treatment completion, also showed benefits in physical and psychological well-being.
A Northwestern University study found that brain cancer patients with malignant gliomas tend to overestimate their quality of life compared to their caregivers. The research suggests that caregivers play a crucial role in providing a more accurate assessment of the patient's well-being.
Results from an Advanced Therapy Access Program demonstrate oncolytic viruses' ability to mediate anti-tumor immunity in humans. The therapy shows strong efficacy against solid tumor cancers, with a clinical benefit rate of 47% and favorable safety profile.
A recent study found that most patients with localized papillary thyroid cancer can expect favorable outcomes without treatment. The 20-year survival rate for these patients is estimated to be around 97%, similar to those who received treatment. Clinicians and patients can feel comfortable considering observation as an option.
Researchers at Thomas Jefferson University have identified a protein, IGF-IR, that regulates motility and invasion of bladder cancer cells. This finding offers a novel molecular target for treating patients with aggressive bladder cancer and may also serve as a tumor biomarker for diagnosis.
Researchers found that minor adjustments to estrogen receptor alpha and p53 genes can lead to precancerous changes in breast tissue. Testing healthy women for these gene variations may help predict future breast cancer risk.
A clinical panel recommends that patients' blood pressure should be closely monitored and controlled before starting angiogenesis inhibitors for cancer treatment. Treating a patient's hypertension before treatment begins and maintaining blood pressure below 140/90 mmHg can help control this side effect.
A new U-M study shows that advanced radiation techniques can treat head and neck cancer effectively while reducing long-term swallowing complications. The study found that up to 88% of patients were cancer-free after three years, with only one patient still requiring a feeding tube.
A study presented at the ARRS 2010 Annual Meeting found that FDG-PET/CT accurately confirmed a suspected colorectal cancer recurrence in 40 out of 71 patients. This early detection enables improved treatment planning and targeted patient care for those with recurrent colorectal cancer.
Researchers at Mayo Clinic are testing new endoscopic optics to detect precancerous polyps and micrometastasis. The pCLE system shows the highest accuracy yet in detecting small polyps, with a specificity of 100%. This technology has the potential to perform virtual biopsies, reducing unnecessary procedures.
Patients who undergo gastric cancer surgery followed by chemotherapy have a lower risk of death and improved disease-free survival compared to those who receive surgery alone. The analysis found an 18% reduction in the risk of death and improved overall survival with chemotherapy.
A study finds that cancer risk in kidney transplant recipients is similar across different immunosuppressive medications, suggesting no single medication is to blame. Patient characteristics such as age and eye color are associated with increased cancer risk.
A new method has been developed to predict which women with DCIS are at high risk of developing more invasive tumors. The study found that two factors - the method of detection and biomarker expression - can identify patients who are most likely to develop invasive cancer within eight years.
A study by Duke University Medical Center found that imaging costs rose faster than overall cancer care for Medicare patients. The use of PET scans increased significantly, with a mean annual growth rate of 36-53% across six cancer types.
The use and costs of diagnostic imaging for Medicare patients with cancer increased substantially between 1999 and 2006. PET scans saw the largest increase, accompanied by a reduction in conventional nuclear medicine tests and stabilized CT scans.
Researchers at Michigan Medicine found that levels of a key type of immune cell can predict which head and neck cancer tumors are most likely to respond to chemotherapy and radiation. The study suggests a way to target treatments to avoid unnecessary side effects, with potential benefits for HPV-negative patients.
The study found a significantly higher incidence of MDS among seniors, with alarming rates of complications such as heart attacks, diabetes, and sepsis. The disease also proved to be costly to treat, with median Medicare bills exceeding $16,000
The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy, which is considered the standard of care for advanced NSCLC. Studies have shown that low expression levels of ERCC1 are related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.
Researchers found that men with multiple affected relatives have a substantially increased risk of developing prostate cancer. The study suggests that doctors should urgently recommend early detection screenings for men with several affected relatives, particularly if they have been diagnosed at a young age.
Researchers identify a mechanism to turn developmental genes on and off as an embryo matures, involving the SUMO/SENP2 system. The study provides new insights into epigenetic control and its role in development, cancer, and neurological diseases.
Researchers have identified three new targets for potential treatment of Ewing's sarcoma, a genetic exchange between chromosomes that results in a fused gene. Additionally, two small molecules have been found to prevent or treat the spread of osteosarcoma, a very aggressive cancer.
Researchers found that metformin decreases insulin levels and inhibits tumor growth in mice exposed to tobacco carcinogens. Metformin reduced lung tumor burden by 40-72% in treated mice.
A new study from Fox Chase Cancer Center suggests that levels of ERCC1 offer a predictive marker of survival in squamous carcinoma of the head and neck. Low ERCC1 levels were associated with increased survival from adjuvant therapy, providing support for personalized medicine in these cancers.
Researchers at UAB Comprehensive Cancer Center discovered four microRNA biomarkers that predict patient survival in colorectal cancer, with differences in outcomes between Caucasian and African-American patients.
A large study found that consuming well-done meat increases the likelihood of developing bladder cancer, especially in people with genetic variants. The risk was higher for those who ate high amounts of red meat and had unfavorable genotypes in the HCA metabolism pathway.
A Phase I clinical trial demonstrated early signs of a strong safety profile and clinical activity for BBI608, a first-in-class cancer cell stemness inhibitor. Nine patients achieved stable disease for at least two months with early signs of tumor regression.
Researchers at Georgetown Lombardi Comprehensive Cancer Center found that a high-fat diet during pregnancy increases breast cancer risk not only in daughters but also in their female and male offspring's daughters. The study suggests that pregnant mothers should eat well-balanced diets to potentially reduce the risk of breast cancer in...
Patient advocates and researchers at Vanderbilt Ingram Cancer Center presented an interactive game show on cancer research to increase awareness, particularly of clinical trials. The event resulted in a 20% increase in participants' knowledge and high engagement rates.
A study by researchers at the University of Texas M.D. Anderson Cancer Center has identified a potential new therapy for brain tumors by analyzing DNA methylation patterns. The discovery may help identify patients with more favorable outcomes and offer a targeted treatment approach.
A TGen and VARI program is studying naturally occurring cancers in dogs to better understand the causes of disease and develop new treatments. The goal is to translate knowledge into therapeutics that can help both humans and animals, with a focus on rare sarcomas and osteosarcoma.
A new multicenter study has found that MDV3100 is safe and effective for patients with castration-resistant prostate cancer. The drug slowed tumor growth, reduced PSA levels, and stabilized disease progression, offering new hope for patients with limited treatment options.
A study found that terminal cancer patients spend most of their remaining lifespan on radiotherapy, but only 26% experience palliation or pain reduction. The authors conclude that radiotherapy is not tailored to individual patient needs, leading to excessive and often uncompleted treatments.
College women are more likely to be vaccinated against HPV if their mothers communicate with them about sex and approve of the vaccine. Young women who thought their mothers would approve were more interested in getting vaccinated, while those whose mothers discussed values in relation to sex showed less interest.
The Southwest Oncology Group's operating grants have been renewed for six years, with a total expected to exceed $120 million over the period. The renewal supports comparative effectiveness research and will primarily fund member institutions nationwide.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a new way to predict prognosis in pediatric leukemia patients using a common complete blood count test. The study found that combining the minimal residual disease indicator and absolute lymphocyte count provides better results than MRD alone, identifyin...
Singapore's A*STAR is collaborating with Italy's Siena Biotech to develop targeted therapies for gastric cancer, leukemia, and osteoporosis. The partnership aims to leverage advanced molecular biology and antibody engineering techniques to create novel treatments.
A new oral anti-cancer drug, vorinostat, is safe to combine with short-term palliative radiotherapy in patients with advanced pelvic cancer. The therapy may enhance the effect of radiotherapy and could become a component of long-term curative treatment. Patients showed tumor response and reduced side effects when treated with vorinostat.
A new study reveals that childhood cancer survivors may experience a significant decrease in life expectancy, with some facing a 10-17 year reduction. The research suggests that recent advancements in treatments and closer monitoring may improve long-term outcomes for these patients.